HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
Recently, HTL Biotechnology completed the registration of the “Sodium DNA Raw Material Main Document” (Polynucleotides) as a medical device (number M2024199-000) in China.
This marks an important milestone for the company in advancing within the Chinese medical device market and pursuing global medical innovation. This achievement, following HTL Biotechnology’s acquisition of a recombinant protein platform (including rhCOL3) further establishes HTL Biotechnology as a global player in the pharmaceutical and biopolymer fields.
Polynucleotides as unique biopolymers, exhibit vast potential in fields such as medical aesthetics, wound repair, and tissue regeneration, owing to its unique repair and regeneration capabilities. Used in injectable medical devices, polynucleotides have regenerative anti-ageing and anti-inflammatory properties. They can also be added to cosmetic formulations to create regenerative cosmetic products.
As a major global supplier of low and high molecular weight polynucleotides, HTL Biotechnology has unique advantages in producing polynucleotide raw materials: HTL Biotechnology’s polynucleotides are produced from deep-sea wild salmon milt, which is reused as a co-product of sustainably fished wild salmon. Its manufacturing process preserves the original DNA structure with a extremely high level of purity and enables a wide range of molecular weights.
HTL Biotechnology operates two state-of-the-art production units for polynucleotides in France, efficiently meeting all customer demands and ensuring an uninterrupted supply chain. Additionally, the company is developing a new production area to further enhance productivity and accommodate the growing market needs.
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
HTL Biotechnology hosted a scientific summit in Chengdu, China, dedicated to PDRN/PN, bringing together more than 130 experts and professionals to discuss the latest scientific advances, regulatory developments and emerging applications.
Driven by the collective commitment of our teams, this report confirms the maturity of an internationally recognized approach, which was recognized this year with the EcoVadis Platinum medal, placing HTL Biotechnology among the top 1% of the world’s most committed companies.